Registration 333-298279
S-1 · 2026-08-12 · 0001493152-26-037435
Terms from the governing filing for this registration; not a claim that the offering is open today.
Company research
BirchBioMed Inc.
CIK 1670747Updated Sep 26, 2026
Filing activity
Latest filing
27 filings on record · S-1, D/A, D, 1-Z, 1-A-W, 1-A POS.
About the company
The Company is a clinical stage biopharmaceutical company focused on developing treatments for scarring (fibrosis, i.e., the overproduction and insufficient breakdown (or remodeling) of ECM proteins, predominantly collagen and fibronectin, within an organ) and related skin disorders; certain autoimmune diseases (diseases consisting of immune responses of an organism against its own cells and tissues); and organ fibrosis. We hold the exclusive, worldwide, non-perpetual pharmaceutical licenses from the University of British Columbia (“UBC”) for two scientific technologies, FS1/FS2 and AI-001. Based on preclinical studies and clinical trials we have conducted to date, we believe these technologies hold the potential for significant medical breakthroughs in the treatment of certain debilitating conditions/disorders in need of novel, better solutions.